Supernus Pharmaceuticals
SUPN
209 hedge funds and large institutions have $1.07B invested in Supernus Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 80 increasing their positions, 71 reducing their positions, and 31 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 71
1.41% more ownership
Funds ownership: 96.21% → 97.62% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 218 → 209 (-9)
11% less capital invested
Capital invested by funds: $1.2B → $1.07B (-$129M)
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
65% less call options, than puts
Call options by funds: $595K | Put options by funds: $1.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$22.5M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$10.4M |
| 3 |
Renaissance Technologies
New York
|
+$6.26M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$5.88M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$5.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$7M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.76M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.75M |
| 4 |
Morgan Stanley
New York
|
-$4.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.82M |
SUPN Hedge Fund Activity: Q3 2020 in Review
209 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2020, worth a combined $1.07B — down 11% from $1.2B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of SUPN and 22 opened new positions — a net loss of 9 holders — while 71 trimmed existing stakes and 80 added.
The largest buyer was Armistice Capital, adding an estimated $22.5M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $7M sold.
- 209 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2020, down from 218 in Q2 2020.
- Funds reported $1.07B of Supernus Pharmaceuticals stock for Q3 2020, down 11% quarter-over-quarter.
- 22 funds opened new Supernus Pharmaceuticals positions in Q3 2020 and 31 closed out, a net change of -9 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2020 was Armistice Capital, an estimated $22.5M added.
- The largest Supernus Pharmaceuticals seller in Q3 2020 was Two Sigma Investments, an estimated $7M sold.
Based on aggregated 13F filings for Q3 2020.